Month: June 2022

HSBC Bank Plc – Form 8.5 (EPT/RI) – Shaftesbury PLC

Written by Customer Service on June 17, 2022. Posted in Mergers And Acquisitions.

FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITYRule 8.5 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Name of exempt principal trader: HSBC Bank Plc(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Shaftesbury PLC(c) Name of the party to the offer with which exempt principal trader is connected: Offerer – Capital & Counties Properties PLC(d) Date dealing undertaken: 16 June 2022(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer? If it is a cash offer or possible cash offer, state “N/A” Yes- Capital & Counties Properties...

Myovant Sciences and Pfizer Announce Publication in The Lancet of Phase 3 SPIRIT 1 and SPIRIT 2 Studies of Once-Daily Relugolix Combination Therapy in Women With Endometriosis-Associated Pain

Written by Customer Service on June 17, 2022. Posted in Public Companies.

BASEL, Switzerland and NEW YORK, June 17, 2022 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that results of the Phase 3 SPIRIT 1 and SPIRIT 2 studies of investigational once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in over 1,200 women with moderate to severe pain associated with endometriosis were published in The Lancet. As previously reported, both studies achieved their co-primary endpoints by demonstrating clinically meaningful reductions in dysmenorrhea (menstrual pain) and non-menstrual pelvic pain in women with endometriosis. SPIRIT 1 and 2 each met their co-primary endpoints with 75% of women in the relugolix combination therapy group in both studies achieving a clinically meaningful reduction in dysmenorrhea...

HSBC Bank Plc – Form 8.5 (EPT/RI) – Capital & Counties Properties PLC

Written by Customer Service on June 17, 2022. Posted in Mergers And Acquisitions.

FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITYRule 8.5 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Name of exempt principal trader: HSBC Bank Plc(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Capital & Counties Properties PLC(c) Name of the party to the offer with which exempt principal trader is connected: Offerer – Capital & Counties Properties PLC(d) Date dealing undertaken: 16 June 2022(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer? If it is a cash offer or possible cash offer, state “N/A” Yes – Shaftesbury...

Interim report – Q2 2021/22 – Half year

Written by Customer Service on June 17, 2022. Posted in Earnings Releases And Operating Results.

Roblon reports better-than-expected revenue and earnings for the first half of 2021/22 and adjusts expectations for the full-yearInterim report – H1 2021/22 (the period 1 November 2021 – 30 April 2022) Highlights of the interim report of the Roblon Group:As expected, the Group was adversely impacted by COVID-19 in the first half of 2021/22, facing logistics challenges, supply shortages of raw materials and other market impacts. Despite these challenges, the Group’s reported revenue and earnings for the first half of 2021/22 exceeded the guidance for the period. This positive development can be attributed to the Composite product group and to the European part of the FOC product group, while the US subsidiary did not perform as expected. As described in company announcement no. 1/2022, the Group acquired the Czech company Vamafil spol....

Proactive news headlines including Lake Resources, Wiluna Mining Corporation, Kazia Therapeutics and Artrya Ltd

Written by Customer Service on June 17, 2022. Posted in Mergers And Acquisitions.

Sydney, June 17, 2022 (GLOBE NEWSWIRE) — Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies:Lake Resources NL (ASX:LKE, OTCQB:LLKKF) has appointed two leading project finance institutions, Citi and J.P. Morgan, as joint coordinators of the proposed debt finance package of its flagship Kachi Lithium Project in Argentina. Click here Wiluna Mining Corporation Ltd (ASX:WMC, OTC:WMXCF) has received strong support for its entitlement issue, with completed applications received from shareholders amounting to A$57,327,216. Click here Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA) has obtained an orphan drug designation (ODD) from the United States Food and Drug Administration (FDA) for the treatment of atypical rhabdoid / teratoid tumours (AT/RT), a rare...

Form 8.5 (EPT/RI) – Global Ports Holding Plc

Written by Customer Service on June 17, 2022. Posted in Mergers And Acquisitions.

FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Name of exempt principal trader: Shore Capital Stockbrokers Ltd(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Global Ports Holding plc(c) Name of the party to the offer with which exempt principal trader is connected: Global Ports Holding plc(d) Date dealing undertaken: 16 June 2022(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer? No 2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER (a) Purchases...

QPR Software Plc’s new shares issued in the rights offering have been registered with the trade register

Written by Customer Service on June 17, 2022. Posted in Public Companies.

QPR SOFTWARE PLC STOCK EXCHANGE RELEASE 17 JUNE 2022 AT 9:00 A.M.NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, HONG KONG, SOUTH AFRICA, SINGAPORE, JAPAN, NEW ZEALAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL.QPR Software Plc’s (the “Company”) 4,010,458 new shares (“New Shares”) issued in the rights offering (“Offering”) have today 17 June 2022 been registered with the trade register maintained by the Finnish Patent and Registration Office. After the registration of the new shares, the total number of shares in the Company is 16,455,321. The new shares carry equal rights to dividends and other distributions of funds possibly carried...

EMGS secures multi-client revenues in Norway

Written by Customer Service on June 17, 2022. Posted in Public Companies.

Electromagnetic Geoservices ASA (“EMGS” or the “Company”) is pleased to announce that the Company has secured approximately USD 1.4 million in revenue from late sales and USD 1.2 million in revenue from a change of control event, all related to its existing multi-client library in Norway. The revenue is expected to be recognised in the second quarter of 2022. ContactAnders Eimstad, CFO, +47 948 25 836 This information is published in accordance with the Norwegian Securities Trading Act § 5-12. About EMGSEMGS, the marine EM market leader, uses its proprietary electromagnetic (EM) technology to support oil and gas companies in their search for offshore hydrocarbons. EMGS supports each stage in the workflow, from survey design and data acquisition to processing and interpretation. The Company’s services enable...

Sandoz Application for proposed biosimilar adalimumab’s high concentration formulation accepted by EMA

Written by Customer Service on June 17, 2022. Posted in Public Companies.

Submission supported by comprehensive analytical and clinical data from new Phase I bridging pharmacokinetics study Adalimumab’s high-concentration 100 mg/mL formulation aims to provide an enhanced yet familiar experience for patients Submission builds on Sandoz’ well established biosimilar immunology portfolio in EuropeBasel, June 17, 2022 — Sandoz, a global leader in generic and biosimilar medicines, today announced that the European Medicines Agency (EMA) has accepted the application for high concentration formulation 100 mg/mL (HCF) of its biosimilar Hyrimoz® (adalimumab) for regulatory review. The application includes all indications covered by the reference medicine*, including rheumatoid arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and uveitis1. Upon approval, the Hyrimoz (100 mg/mL) citrate-free HCF...

Cresemba® sales in Asia Pacific region trigger sales milestone payment to Basilea from Pfizer

Written by Customer Service on June 17, 2022. Posted in Public Companies.

Basel/Allschwil, Switzerland, June 17, 2022 Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company, announced today that the sales of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer Inc. (NYSE: PFE, “Pfizer”) in the Asia Pacific region, exceeded the threshold triggering the first sales milestone payment for this region of USD 1.25 million. David Veitch, Basilea’s Chief Executive Officer, stated: “We are very pleased with the commercial progress of Cresemba, which has now triggered the first sales milestone payment from Pfizer for the Asia Pacific region. The continued growth in the established markets in the US and Europe and the increasing contributions from new regions, such as Asia Pacific, confirm that Cresemba is serving a high medical need around the world.” The license agreement...

Month: June 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals